

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A peptide having a sequence of at most 44 amino acid residues comprising a motif of the formula

X^1-X^2 -Cys- $X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}-X^{13}-X^{14}-X^{15}-X^{16}-X^{17}$ -Cys- $X^{18}-X^{19}$,

wherein

X can be an amino acid sequence or a single amino acid residue selected either from Group 1 consisting of Ala, Gly, and Ser, Group 2 consisting of Arg and Lys, Group 3 consisting of His, Ile, Leu, Met, Phe, Pro, Thr, Val, Trp, and Tyr,

Group 4 consisting of Asn and Gln , or

Group 5 consisting of Ala, Asn, Arg, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val,

wherein

X^1 can be represented by a sequence consisting of 2-5 amino acid residues or an amino acid residue selected from Group 2;

X² is selected from Group 5 or Group 3;
X³, X¹⁵ and X⁴ are selected from Group 1;
X⁵ is Thr or selected from from Group 1;
X⁶, X¹¹, X¹², X¹³ and X⁷ are selected from Group 3;
X⁸ and X¹⁷ are selected from Group 1, 3 or 4;
X⁹ is selected from from Group 5, 1 or 3;
X¹⁰ is selected from from Group 2, 3 or 4;
X¹⁴ is Ser or selected from from Group 3;
X¹⁶ and X¹⁸ is selected from Group 1 or 3
X¹⁹ can be represented by a sequence consisting of 2-5 amino acid residues or a single amino acid residue selected from Group 5, 2, or 4,

with the proviso, that when X¹ includes Pro, then X¹⁹ is Gln.

2. - 26. (Cancelled)

27. (Currently Amended) The peptide according to ~~any of the~~
~~claims~~ claim 1 ~~1-26~~, wherein said peptide has the sequence
KQGRHFCGGALIHARFVMTAASCFR (SEQ ID NO: 595).

28. (Currently Amended) The peptide according to ~~any of the~~
~~claims~~ claim 1 ~~1-26~~, wherein said peptide has the sequence
KQGRPFCGGALIHARFVMTAASCFR (SEQ ID NO: 596).

29. (Currently Amended) The peptide according to ~~any of the~~
~~claims~~ claim 1 ~~1-26~~, wherein said peptide has the sequence
KQGRHFCEGGALIHPRFVMTAASCFR (SEQ ID NO: 597).

30. (Currently Amended) The peptide according to ~~any of the~~
~~claims~~ claim 1 ~~1-26~~, wherein said peptide has the sequence
KQGRPFCEGGALIHPRFVMTAASCFR (SEQ ID NO: 598).

31. (Currently Amended) The peptide according to ~~any of the~~
~~claims~~ claim 1 ~~1-26~~, wherein said peptide has the sequence
RFCSAATLVFRPHVLGACFPRGQK (SEQ ID NO: 599).

32. (Currently Amended) The peptide according to ~~any of the~~
~~claims~~ claim 1 ~~1-26~~, wherein said peptide has the sequence
NQGRPFCEGALVHPRFVLTAASCFR (SEQ ID NO: 600).

33. (Currently Amended) The peptide according to ~~any of the~~
~~claims~~ claim 1 ~~1-26~~, wherein said peptide has the sequence
KQGRPFCEGALVHPRFVLTAASCFQ (SEQ ID NO: 601).

34. (Currently Amended) The peptide according to ~~any of the~~
~~claims~~ claim 1 ~~1-26~~, wherein said peptide has the sequence
NQGRPFCEGALVHPRFVLTAASCFQ (SEQ ID NO: 602).

35. (Currently Amended) The peptide according to ~~any of the~~
~~claims~~ claim 1 ~~1-26~~, wherein said peptide has the sequence
KQGRPFCAGALVHPQFVLTAASCFR (SEQ ID NO: 603).

36. (Currently Amended) The peptide according to ~~any of the~~
~~claims~~ claim 1 ~~1-26~~, wherein said peptide has the sequence
LRGGHFCGATLIAPNFVMSAAHCVA (SEQ ID NO: 604).

37. (Currently Amended) The peptide according to ~~any of the~~
~~claims~~ claim 1 ~~1-26~~, wherein said peptide has the sequence
RRGGHFCGATLIARNFVMSAVHCVN (SEQ ID NO: 605).

38. (Currently Amended) The peptide according to ~~any of the~~
~~claims~~ claim 1 ~~1-26~~, wherein said peptide has the sequence
RSREYRCGGTLVSQRYILTAASCAA (SEQ ID NO: 606).

39. (Currently Amended) The peptide according to ~~any of the~~
~~claims~~ claim 1 ~~1-26~~, wherein said peptide has the sequence
NQGRHFCGGALIHARFVMTAASCFQ (SEQ ID NO: 594).

40. (Currently Amended) The peptide according to ~~any of the~~
~~claims~~ claim 1 ~~1-26~~, wherein said peptide has the sequence
KQGRPFCAGALVHPREFVLTAASCFR (SEQ ID NO: 593).

41. - 52. (Cancelled)

53. (Currently Amended) The peptide according to ~~any of the~~
~~claims~~ claim 1 ~~1-52~~, wherein said peptide is capable of
inhibiting the secretion of cytokine IL-6 from monocytes.

54. (Currently Amended) The peptide according to ~~any of the~~
~~claims~~ claim 1 ~~1-52~~, wherein said peptide is capable of
stimulating the secretion of cytokine IL-6 from monocytes.

55. - 56. (Cancelled)

57. (Currently Amended) A method of treatment of gram-
negative bacterial infection comprising administering to an
individual in need ~~Use of~~ one or more peptides as defined in
~~any of the claims 1-54~~ claim 1 ~~for the manufacture of a~~
~~medicament for the treatment of Gram negative bacterial~~
~~infection.~~

58. (Currently Amended) A method of treatment of gram-
positive bacterial infection comprising administering to an
individual in need ~~Use of~~ one or more peptides as defined in
~~any of the claims 1-54~~ claim 1 ~~for the manufacture of a~~

~~medicament for the treatment of Gram positive bacterial
infection.~~

59. - 72. (Cancelled)

73. (Currently Amended) A pharmaceutical composition
comprising a peptide as defined in claim 1~~-claims 1-54~~.